Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
4.78
-0.01 (-0.21%)
At close: Aug 12, 2022 4:00 PM
4.75
-0.03 (-0.63%)
After-hours: Aug 12, 2022 6:38 PM EDT
-0.21%
Market Cap 443.83M
Revenue (ttm) 4.54M
Net Income (ttm) -120.78M
Shares Out 92.85M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,864,431
Open 5.13
Previous Close 4.79
Day's Range 4.70 - 5.34
52-Week Range 2.93 - 25.39
Beta n/a
Analysts Buy
Price Target 15.81 (+230.8%)
Earnings Date Sep 6, 2022

About ABSI

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington. [Read more...]

Industry Biotechnology
IPO Date Jul 22, 2021
Employees 211
Stock Exchange NASDAQ
Ticker Symbol ABSI
Full Company Profile

Financial Performance

In 2021, Absci's revenue was $4.78 million, an increase of 0.04% compared to the previous year's $4.78 million. Losses were -$100.96 million, 603.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ABSI stock is "Buy." The 12-month stock price forecast is 15.81, which is an increase of 230.75% from the latest price.

Price Target
$15.81
(230.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Absci Reports Second Quarter 2022 Financial Results and Business Update

Exceeded annual Active Program guidance with ten programs signed year-to-date

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Other symbols: AXLADICEFRLNPLRX

Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the t...

Absci to Participate in the SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event

VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the t...

Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires

VANCOUVER, Wash. and NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the t...

Absci Enters Multi-Program Collaboration with Emerging Biotech Partner

Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology

Absci Reports First Quarter 2022 Financial and Operating Results

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic pot...

Vancouver, Wash.-based biotech Absci opens new AI Research Lab in New York City

Absci, the Vancouver, Wash.-based biotech that provides drug and drug target discovery services to other companies, has opened a lab in New York City. The company announced the opening of the Absci AI R...

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Gr...

Financial Highlights of the year ended December 31, 2021: Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% Gross profit amounted to RMB651.0 million, represen...

Here's Why Absci Corp Shares Are Falling

Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share.

Absci Reports Full Year 2021 Financial and Operating Results

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic p...

Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA

Absci to present in-silico drug discovery technology at NVIDIA GTC

Absci Appoints Dr. Andreas Busch to Board of Directors

Dr. Busch brings deep operational expertise in drug discovery to Absci's Board Dr. Busch brings deep operational expertise in drug discovery to Absci's Board

Absci to Present at Global AI Conference NVIDIA GTC

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic po...

Is a Surprise Coming for Absci (ABSI) This Earnings Season?

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic po...

Absci to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic po...

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

Other symbols: MRK

Absci Corp up 50% after announcing research collaboration with Merck

Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company...

Other symbols: MRK

ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today

Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK). The post ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Ha...

Why Absci Shares Are Soaring Today

Absci Corp (NASDAQ: ABSI) is trading higher Friday after the company announced a research collaboration with Merck & Co Inc (NYSE: MRK). The collaboration will utilize Absci's AI-powered Integrated Drug...

Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments

Shares of Absci Corp. ABSI, -12.78% skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees...

Absci Announces Research Collaboration with Merck

Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technologies Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technol...